Suthinee Ithimakin

1.1k total citations · 1 hit paper
28 papers, 673 citations indexed

About

Suthinee Ithimakin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Suthinee Ithimakin has authored 28 papers receiving a total of 673 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Suthinee Ithimakin's work include Nausea and vomiting management (4 papers), Cancer Treatment and Pharmacology (4 papers) and Breast Cancer Treatment Studies (4 papers). Suthinee Ithimakin is often cited by papers focused on Nausea and vomiting management (4 papers), Cancer Treatment and Pharmacology (4 papers) and Breast Cancer Treatment Studies (4 papers). Suthinee Ithimakin collaborates with scholars based in Thailand, United States and Singapore. Suthinee Ithimakin's co-authors include Amanda K. Paulson, Susan Chung, Hayley J. Paholak, Nader Tawakkol, Qin Zen, N. Lynn Henry, Ahmed A. Quraishi, Rosemarie C. D'Angelo, Hasan Körkaya and Max S. Wicha and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cell and Cancer Research.

In The Last Decade

Suthinee Ithimakin

26 papers receiving 662 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population

2012 427 citations Hasan Körkaya, April Davis et al. Molecular Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suthinee Ithimakin Thailand	8	439	240	168	111	79	28	673
Xueying Wang China	8	212 0.5×	260 1.1×	128 0.8×	123 1.1×	95 1.2×	29	683
Eleonora Lai Italy	14	315 0.7×	205 0.9×	154 0.9×	93 0.8×	145 1.8×	46	572
Angela Kueck United States	11	415 0.9×	425 1.8×	229 1.4×	87 0.8×	35 0.4×	14	895
Satu Tiainen Finland	10	264 0.6×	269 1.1×	87 0.5×	232 2.1×	70 0.9×	17	596
Songtao Lai China	11	251 0.6×	314 1.3×	168 1.0×	105 0.9×	90 1.1×	21	645
Alessandro Villanucci Italy	14	209 0.5×	189 0.8×	110 0.7×	113 1.0×	128 1.6×	35	696
Ildiko Csiki United States	9	203 0.5×	229 1.0×	121 0.7×	130 1.2×	104 1.3×	25	663
Stella Logotheti Germany	16	212 0.5×	416 1.7×	198 1.2×	57 0.5×	65 0.8×	33	671
Roberta Sarmiento Italy	11	235 0.5×	190 0.8×	135 0.8×	79 0.7×	71 0.9×	19	591
Tarah J. Ballinger United States	13	383 0.9×	285 1.2×	217 1.3×	51 0.5×	159 2.0×	49	727

Countries citing papers authored by Suthinee Ithimakin

Since Specialization

Citations

This map shows the geographic impact of Suthinee Ithimakin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suthinee Ithimakin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suthinee Ithimakin more than expected).

Fields of papers citing papers by Suthinee Ithimakin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suthinee Ithimakin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suthinee Ithimakin. The network helps show where Suthinee Ithimakin may publish in the future.

Co-authorship network of co-authors of Suthinee Ithimakin

This figure shows the co-authorship network connecting the top 25 collaborators of Suthinee Ithimakin. A scholar is included among the top collaborators of Suthinee Ithimakin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suthinee Ithimakin. Suthinee Ithimakin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dechaphunkul, Arunee, et al.. (2025). Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study. International Journal of Breast Cancer. 2025(1). 5597051–5597051.

Chularojanamontri, Leena, et al.. (2025). Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome. BMC Cancer. 25(1). 275–275. 1 indexed citations

Thephamongkhol, Kullathorn, et al.. (2025). Efficacy and Safety of Short Intravenous Hydration for Preventing Nephrotoxicity From High-Dose Cisplatin: A Randomized, Open-Label, Phase II Trial. JCO Global Oncology. 11(11). e2400515–e2400515. 1 indexed citations

Ithimakin, Suthinee, et al.. (2024). Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand. BMC Cancer. 24(1). 1018–1018. 4 indexed citations

Rujitharanawong, Chuda, et al.. (2024). Efficacy and safety of nail gutter therapy and topical timolol for treating epidermal growth factor receptor inhibitor-induced nail changes: A randomized, single-blind, intraindividual study. Journal of the American Academy of Dermatology. 92(3). 617–619. 1 indexed citations

Ithimakin, Suthinee, et al.. (2024). 41P Impact of HER2-low and HER2-zero status on metastatic hormonal receptor-positive breast cancer patients treated with first-line aromatase inhibitors, with or without CDK4/6 inhibitors: A multicenter retrospective analysis. Annals of Oncology. 35. S1420–S1420. 1 indexed citations

Ithimakin, Suthinee, et al.. (2023). 439P Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention. Annals of Oncology. 34. S1634–S1635. 1 indexed citations

Ithimakin, Suthinee, Napa Parinyanitikul, Sung‐Bae Kim, et al.. (2022). Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories. Journal of Breast Cancer. 25(3). 207–207. 5 indexed citations

Ngamphaiboon, Nuttapong, et al.. (2021). Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis. BMC Cancer. 21(1). 1275–1275. 16 indexed citations

10.

Ithimakin, Suthinee, et al.. (2020). Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Supportive Care in Cancer. 28(11). 5335–5342. 20 indexed citations

11.

Akaraviputh, Thawatchai, Vitoon Chinswangwatanakul, Ananya Pongpaibul, et al.. (2020). Predictive significance of cancer related-inflammatory markers in locally advanced rectal cancer. World Journal of Gastrointestinal Surgery. 12(9). 390–396. 11 indexed citations

12.

Petsuksiri, Janjira, et al.. (2019). Post-Operative Concurrent Chemoradiation for Patients with Non-Squamous Cell Carcinoma of Head and Neck: A Retrospective Cohort of the Uncommon Cancers. Asian Pacific Journal of Cancer Prevention. 20(6). 1727–1734. 1 indexed citations

13.

Thuwajit, Peti, et al.. (2018). Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. BMC Cancer. 18(1). 231–231. 35 indexed citations

14.

Srinonprasert, Varalak, et al.. (2017). Risk Factors for Chemotherapy-Related Toxicity and Adverse Events in Elderly Thai Cancer Patients: A Prospective Study. Oncology. 94(3). 149–160. 18 indexed citations

15.

Ithimakin, Suthinee, et al.. (2016). Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World Journal of Surgical Oncology. 14(1). 223–223. 48 indexed citations

16.

Srimuninnimit, Vichien, Charuwan Akewanlop, Suthinee Ithimakin, et al.. (2016). Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. Supportive Care in Cancer. 25(2). 459–464. 41 indexed citations

17.

Körkaya, Hasan, April Davis, Fayaz Malik, et al.. (2012). Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population. Molecular Cell. 47(4). 570–584. 427 indexed citations breakdown →

18.

Malik, Fayaz, Suthinee Ithimakin, Kathleen C. Day, et al.. (2012). Abstract 3470: HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab. Cancer Research. 72(8_Supplement). 3470–3470. 1 indexed citations

19.

Ithimakin, Suthinee, et al.. (2011). Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. Supportive Care in Cancer. 20(4). 849–855. 7 indexed citations

20.

Srimuninnimit, Vichien, et al.. (2010). Phase II study of the combination of gemcitabine plus carboplatin as neoadjuvant treatment in locally advanced breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 652–652. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact